Loading financial data...

Arcturus Therapeutics Holdings Inc. (ARCT) Financial Statements | Global Financial Data

Arcturus Therapeutics Holdings Inc.

ARCTSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1768224

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$166.8M	$206.0M	$12.4M	$12.4M	$20.8M
Research and Development Expense	$192.1M	$147.8M	$173.8M	$173.8M	$33.6M
Operating Expenses	$245.0M	$193.8M	$215.2M	$215.2M	$46.3M
Operating Income (Loss)	-$78.2M	$12.2M	-$202.9M	-$202.9M	-$25.5M
Other Nonoperating Income (Expense)	$16.6M	-$420.0K	-$1.9M	-$1.9M	-$446.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$27.9M	$10.6M	-$203.7M	-$203.7M	—
Income Tax Expense (Benefit)	$1.8M	$1.3M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$344.1M	$429.4M	$450.4M	$392.8M	$476.5M
Assets, Current	$306.0M	$386.6M	$403.3M	$379.0M	$467.8M
Cash and Cash Equivalents, at Carrying Value	$292.0M	$391.9M	$370.5M	$370.5M	$71.4M
Accounts Receivable, after Allowance for Credit Loss, Current	$4.0M	$32.1M	$2.8M	$3.4M	$2.1M
Liabilities	$103.1M	$150.9M	$180.1M	$164.6M	$79.9M
Liabilities, Current	$65.5M	$82.0M	$127.0M	$99.5M	$49.5M
Long-term Debt	—	—	—	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$18.1M	$32.0M	-$135.0M	-$135.0M	-$6.4M
Net Cash Provided by (Used in) Investing Activities	-$2.9M	-$7.7M	-$3.4M	-$3.4M	-$818.0K
Net Cash Provided by (Used in) Financing Activities	-$24.1M	-$2.9M	$48.0M	$48.0M	$41.9M
Payments to Acquire Property, Plant, and Equipment	$2.9M	$7.7M	$3.4M	$3.4M	$818.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)